NEW YORK (TheStreet) -- Eli Lilly (LLY) shares are down -0.5% to $59.42 on Wednesday after the company said that its liver cancer treatment, Cyramza, failed to meet its primary goals in a Phase 3 study.
Rates of survival from patients who received the Cyramza treatment and those who received placebos were statistically insignificant, according to the company.
TheStreet Ratings team rates LILLY (ELI) & CO as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate LILLY (ELI) & CO (LLY) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
Highlights from the analysis by TheStreet Ratings Team goes as follows: